Barclays analyst Matt Miksic lowered the firm’s price target on Globus Medical (GMED) to $83 from $86 and keeps an Equal Weight rating on the shares. The firm’s revised estimates reflect the six-month delay in planned synergies, due to the later close of the NuVasive (NUVA) acquisition.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMED:
- Globus Medical price target raised to $58 from $53 at Truist
- Globus Medical price target raised to $71 from $67 at Canaccord
- Globus Medical price target lowered to $53 from $60 at Morgan Stanley
- Globus Medical price target lowered to $53 from $58 at Truist
- Globus Medical backs FY23 EPS view $2.30, consensus $2.32
